IBB vs SQQQ

iShares Biotechnology ETF vs ProShares UltraPro Short QQQ

Quick take
  • • IBB has the lower expense ratio at 0.44% vs 0.94% for SQQQ.
  • • SQQQ pays a higher dividend yield (7.78%).

Side-by-side metrics

MetricIBBSQQQ
Expense ratio
Annual fee. Lower is better.
0.44%0.94%
Dividend yield
Trailing 12-month yield.
0.16%7.78%
AUM
Assets under management — bigger funds are typically more liquid.
$11.50B$2.04B
YTD return
30.22%-35.13%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.60-3.21
P/E ratio
25.48—
Last price
$217.75$39.82
Inception
——
Issuer
iSharesProShares

IBB top holdings

Top holdings · IBB
GILDGilead Sciences Inc8.94%
AMGNAmgen Inc8.31%
VRTXVertex Pharmaceuticals Inc7.87%
REGNRegeneron Pharmaceuticals Inc6.24%
MRNAModerna Inc5.49%
NTRANatera Inc3.78%
ARGXargenx SE ADR3.36%
BIIBBiogen Inc2.52%
RVMDRevolution Medicines Inc Ordinary Shares2.50%
ILMNIllumina Inc2.41%
Sector breakdown · IBB
Healthcare100.0%

SQQQ top holdings

Holdings data unavailable for SQQQ.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About SQQQ

SQQQ (ProShares UltraPro Short QQQ) is 3x inverse daily performance of the Nasdaq-100. Managed by ProShares, the fund carries $2.0B in assets under management, an expense ratio of 0.94%, a dividend yield of 7.78%.